Sensus Healthcare, Inc.
NASDAQ:SRTSMedical - Devices
+$0.09 today
- Market cap
- $53.01M
- Beta
- 1.09
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.47
Volume 0.08M
Average 0.06M
SRTS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Sensus Healthcare, Inc.NASDAQ: SRTS
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $1.35M rose 63.7% year over year, ahead of the -148.8% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 5.3% of revenue in FY2025, up 0.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +63.7% holds above the trailing-twelve-month pace of -148.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.47M) USD
- Year-over-year change
- -172.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.47M) | -172.7% |
| FY2024 | 2024-12-31 | 2.02M | +174.0% |
| FY2023 | 2023-12-31 | (2.73M) | -441.4% |
| FY2022 | 2022-12-31 | 799K | -16.9% |
| FY2021 | 2021-12-31 | 962K | — |
Accounts Payables vs competitors
How SRTS compares with its peers on the latest reported figures
- SRTS's LTM Mar 2026 accounts payables of $943K is the 4th largest of the 6 companies compared; the peer median is $424K.
- Its year-over-year change of -148.8% is the lowest of 6, against a peer median of +8.7%.
- Accounts payables amounts to 4.2% of revenue for SRTS, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MDAISpectral AI, Inc. | LTM Mar 2026 | $1.67M | +663.8% | — | 10.0% |
| LTM Mar 2026 | $1.59M | +8.7% | — | 1.1% | |
| LTM Jun 2026 | $1.17M | +308.6% | — | 1.5% | |
| LTM Mar 2026 | $943K | -148.8% | — | 4.2% | |
BDMDBaird Medical Investment Holdings Limited | FY2025 | $483.95K | -33.5% | — | 2.1% |
| LTM Mar 2026 | $424K | -76.4% | — | — | |
| Peer median (excluding SRTS) | $424K | +8.7% | — | 1.8% | |
Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.12M | 24.24M | 485K | 6.65M | (7.72M) |
| Depreciation & Amortization | 613K | 509K | 461K | 432K | 626K |
| Deferred Income Tax | 0 | (1.71M) | (427K) | (57K) | (1.88M) |
| Stock-Based Compensation | 415K | 187K | 328K | 323K | 295K |
| Change in Working Capital | (6.14M) | (12.92M) | (3.56M) | (8.55M) | 8.66M |
| Accounts Receivables | (8.43M) | (5.31M) | 6.65M | (9.21M) | 13.65M |
| Inventory | 2.74M | (3.19M) | (8.58M) | 268K | (4.64M) |
| Accounts Payables | 962K | 799K | (2.73M) | 2.02M | (1.47M) |
| Other Working Capital | (1.4M) | (5.22M) | 1.1M | (1.63M) | 1.12M |
| Other Non-Cash Items | 705K | (11.72M) | 568K | 378K | 547K |
| Operating Cash Flow | (286K) | (1.41M) | (2.15M) | (831K) | 528K |
| Capital Expenditures | (128K) | (159K) | (229K) | (276K) | (196K) |
| Acquisitions (Net) | 257K | 15M | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 42K | 0 | 0 |
| Investing Cash Flow | 129K | 14.84M | (187K) | (276K) | (196K) |
| Debt Repayment | (216K) | (51K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 67K | 0 |
| Common Stock Repurchased | (15K) | (3M) | (27K) | 0 | (300K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 622K | (13K) | (52K) | (5K) |
| Financing Cash Flow | (231K) | (2.43M) | (40K) | 15K | (305K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (388K) | 11M | (2.37M) | (1.09M) | 27K |
| Free Cash Flow | (414K) | (1.57M) | (2.37M) | (1.11M) | 332K |
Sensus Healthcare, Inc.
NASDAQ:SRTS
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.